Dr Giannis Mountzios speaks to ecancer about the phase 3 DeLLphi-304 study.

This study demonstrated that tarlatamab significantly improved overall survival compared with chemotherapy in patients with relapsed small cell lung cancer (SCLC), independent of chemotherapy-free interval or prior anti–PD-(L)1 therapy.

Dr Mountzios highlights that across all subgroups, tarlatamab showed higher response rates, reduced risk of death, and fewer severe treatment-related adverse events than standard chemotherapy.

These consistent outcomes, including in platinum-resistant disease, support tarlatamab as a new standard of care for second-line SCLC.